<VariationArchive VariationID="371084" VariationName="NM_004937.3(CTNS):c.646dup (p.Thr216fs)" VariationType="Duplication" Accession="VCV000371084" Version="12" RecordType="classified" NumberOfSubmissions="5" NumberOfSubmitters="5" DateLastUpdated="2024-07-29" DateCreated="2017-01-06" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="358431" VariationID="371084">
      <GeneList>
        <Gene Symbol="CTNS" FullName="cystinosin, lysosomal cystine transporter" GeneID="1497" HGNC_ID="HGNC:2518" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>17p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3636459" stop="3663103" display_start="3636459" display_stop="3663103" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3539761" stop="3566396" display_start="3539761" display_stop="3566396" Strand="+" />
          </Location>
          <OMIM>606272</OMIM>
        </Gene>
        <Gene Symbol="CTNS-AS1" FullName="CTNS antisense RNA 1" GeneID="105371492" HGNC_ID="HGNC:56090" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>17p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3652550" stop="3658015" display_start="3652550" display_stop="3658015" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_004937.3(CTNS):c.646dup (p.Thr216fs)</Name>
      <CanonicalSPDI>NC_000017.11:3656759:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>17p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3656759" stop="3656760" display_start="3656759" display_stop="3656760" variantLength="1" positionVCF="3656759" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3560053" stop="3560054" display_start="3560053" display_stop="3560054" variantLength="1" positionVCF="3560053" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>T216fs</ProteinChange>
      <ProteinChange>T69fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.3560054dup" Assembly="GRCh37">
            <Expression>NC_000017.10:g.3560054dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.3656760dup" Assembly="GRCh38">
            <Expression>NC_000017.11:g.3656760dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012489.2" sequenceAccession="NG_012489" sequenceVersion="2" change="g.25293dup">
            <Expression>NG_012489.2:g.25293dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001031681.3" sequenceAccession="NM_001031681" sequenceVersion="3" change="c.646dup">
            <Expression>NM_001031681.3:c.646dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001026851.2" sequenceAccession="NP_001026851" sequenceVersion="2" change="p.Thr216fs">
            <Expression>NP_001026851.2:p.Thr216fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374492.1" sequenceAccession="NM_001374492" sequenceVersion="1" change="c.646dup">
            <Expression>NM_001374492.1:c.646dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361421.1" sequenceAccession="NP_001361421" sequenceVersion="1" change="p.Thr216fs">
            <Expression>NP_001361421.1:p.Thr216fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374493.1" sequenceAccession="NM_001374493" sequenceVersion="1" change="c.205dup">
            <Expression>NM_001374493.1:c.205dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361422.1" sequenceAccession="NP_001361422" sequenceVersion="1" change="p.Thr69fs">
            <Expression>NP_001361422.1:p.Thr69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374494.1" sequenceAccession="NM_001374494" sequenceVersion="1" change="c.205dup">
            <Expression>NM_001374494.1:c.205dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361423.1" sequenceAccession="NP_001361423" sequenceVersion="1" change="p.Thr69fs">
            <Expression>NP_001361423.1:p.Thr69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374495.1" sequenceAccession="NM_001374495" sequenceVersion="1" change="c.205dup">
            <Expression>NM_001374495.1:c.205dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361424.1" sequenceAccession="NP_001361424" sequenceVersion="1" change="p.Thr69fs">
            <Expression>NP_001361424.1:p.Thr69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374496.1" sequenceAccession="NM_001374496" sequenceVersion="1" change="c.205dup">
            <Expression>NM_001374496.1:c.205dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361425.1" sequenceAccession="NP_001361425" sequenceVersion="1" change="p.Thr69fs">
            <Expression>NP_001361425.1:p.Thr69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.3" sequenceAccession="NM_004937" sequenceVersion="3" change="c.646dup" MANESelect="true">
            <Expression>NM_004937.3:c.646dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004928.2" sequenceAccession="NP_004928" sequenceVersion="2" change="p.Thr216fs">
            <Expression>NP_004928.2:p.Thr216fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.2" sequenceAccession="NM_004937" sequenceVersion="2" change="c.646dup">
            <Expression>NM_004937.2:c.646dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA16041835" DB="ClinGen" />
        <XRef Type="rs" ID="893207601" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00002" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004937.3(CTNS):c.646dup (p.Thr216fs) AND Nephropathic cystinosis" Accession="RCV000411977" Version="11">
        <ClassifiedConditionList TraitSetID="1222">
          <ClassifiedCondition DB="MedGen" ID="C2931187">Nephropathic cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-12-04" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.646dup (p.Thr216fs) AND Cystinosis" Accession="RCV001833492" Version="9">
        <ClassifiedConditionList TraitSetID="31961">
          <ClassifiedCondition DB="MedGen" ID="C4316899">Cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2020-07-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.646dup (p.Thr216fs) AND multiple conditions" Accession="RCV002244854" Version="11">
        <ClassifiedConditionList TraitSetID="10684">
          <ClassifiedCondition DB="MedGen" ID="C0268626">Juvenile nephropathic cystinosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2931187">Nephropathic cystinosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2931013">Ocular cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.646dup (p.Thr216fs) AND multiple conditions" Accession="RCV002523866" Version="9">
        <ClassifiedConditionList TraitSetID="65712">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268626">Juvenile nephropathic cystinosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2931013">Ocular cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-07-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-12-04" NumberOfSubmissions="5" NumberOfSubmitters="5" DateCreated="2017-01-06" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">18178779</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19863563</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27102039</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27858370</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9537412</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9792862</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="10684" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1215" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cystinosis, ocular nonnephropathic</ElementValue>
                <XRef ID="Cystinosis%2C+Ocular+Nonnephropathic/2080" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ocular cystinosis</ElementValue>
                <XRef ID="MONDO:0009064" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, adult, nonnephropathic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, benign, nonnephropathic</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9756" />
                <XRef ID="9756" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411641" DB="Orphanet" />
              <XRef ID="C2931013" DB="MedGen" />
              <XRef ID="MONDO:0009064" DB="MONDO" />
              <XRef Type="MIM" ID="219750" DB="OMIM" />
            </Trait>
            <Trait ID="1216" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Juvenile nephropathic cystinosis</ElementValue>
                <XRef ID="Juvenile+nephropathic+cystinosis/8698" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009066" DB="MONDO" />
                <XRef ID="22830006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE</ElementValue>
                <XRef Type="MIM" ID="219900" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0008" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17685" />
                <XRef ID="17685" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411634" DB="Orphanet" />
              <XRef ID="C0268626" DB="MedGen" />
              <XRef ID="MONDO:0009066" DB="MONDO" />
              <XRef Type="MIM" ID="219900" DB="OMIM" />
            </Trait>
            <Trait ID="15909" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Nephropathic cystinosis</ElementValue>
                <XRef ID="54105" DB="GeneTests" />
                <XRef ID="MONDO:0100151" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lysosomal cystine transport protein, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosin, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden Lignac Kaufmann disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden-Kaufmann-Lignac syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTNS</ElementValue>
                <XRef ID="GTR000529128" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="219800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10074" />
                <XRef ID="10074" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411629" DB="Orphanet" />
              <XRef ID="C2931187" DB="MedGen" />
              <XRef ID="MONDO:0100151" DB="MONDO" />
              <XRef Type="MIM" ID="219800" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="31961" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="6309" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cystinosis</ElementValue>
                <XRef ID="3377" DB="GeneTests" />
                <XRef ID="MONDO:0016239" DB="MONDO" />
                <XRef ID="190681003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine diathesis</ElementValue>
                <XRef ID="D003554" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine storage disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinoses</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6236" />
                <XRef ID="6236" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="C4316899" DB="MedGen" />
              <XRef ID="MONDO:0016239" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="65712" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1215" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cystinosis, ocular nonnephropathic</ElementValue>
                <XRef ID="Cystinosis%2C+Ocular+Nonnephropathic/2080" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ocular cystinosis</ElementValue>
                <XRef ID="MONDO:0009064" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, adult, nonnephropathic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, benign, nonnephropathic</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9756" />
                <XRef ID="9756" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411641" DB="Orphanet" />
              <XRef ID="C2931013" DB="MedGen" />
              <XRef ID="MONDO:0009064" DB="MONDO" />
              <XRef Type="MIM" ID="219750" DB="OMIM" />
            </Trait>
            <Trait ID="1216" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Juvenile nephropathic cystinosis</ElementValue>
                <XRef ID="Juvenile+nephropathic+cystinosis/8698" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009066" DB="MONDO" />
                <XRef ID="22830006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE</ElementValue>
                <XRef Type="MIM" ID="219900" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0008" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17685" />
                <XRef ID="17685" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411634" DB="Orphanet" />
              <XRef ID="C0268626" DB="MedGen" />
              <XRef ID="MONDO:0009066" DB="MONDO" />
              <XRef Type="MIM" ID="219900" DB="OMIM" />
            </Trait>
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1222" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15909" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Nephropathic cystinosis</ElementValue>
                <XRef ID="54105" DB="GeneTests" />
                <XRef ID="MONDO:0100151" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lysosomal cystine transport protein, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosin, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden Lignac Kaufmann disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden-Kaufmann-Lignac syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTNS</ElementValue>
                <XRef ID="GTR000529128" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="219800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10074" />
                <XRef ID="10074" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411629" DB="Orphanet" />
              <XRef ID="C2931187" DB="MedGen" />
              <XRef ID="MONDO:0100151" DB="MONDO" />
              <XRef Type="MIM" ID="219800" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="950308" SubmissionDate="2016-11-23" DateLastUpdated="2022-12-24" DateCreated="2017-01-06">
        <ClinVarSubmissionID localKey="25806|OMIM:219800" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000486558" DateUpdated="2022-12-24" DateCreated="2017-01-06" Type="SCV" Version="2" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-06-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19863563</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9792862</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rb7nm21v/ar_xl2015criteria.pdf</URL>
            <CitationText>mdi-5618_320494_Counsyl Autosomal and X-linked Recessive Disease Classification criteria (2015).pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.2:c.646dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219800" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Counsyl2016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1604614" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3663625|MedGen:C0950123;C1857413;C0268626" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000832678" DateUpdated="2024-02-28" DateCreated="2018-10-10" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-07-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9792862</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18178779</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19863563</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27858370</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9537412</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27102039</ID>
          </Citation>
          <Comment>This variant is present in population databases (no rsID available, gnomAD 0.003%). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 371084). This variant is also known as c.985insA, p.Thr216Asn. This premature translational stop signal has been observed in individuals with cystinosis (PMID: 9792862, 18178779, 19863563, 27858370). This sequence change creates a premature translational stop signal (p.Thr216Asnfs*12) in the CTNS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNS are known to be pathogenic (PMID: 9537412, 27102039).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.3560053_3560054insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1857413" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268626" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB6933842</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4081291" SubmissionDate="2022-02-09" DateLastUpdated="2022-02-13" DateCreated="2022-02-13">
        <ClinVarSubmissionID localKey="NM_004937.3:c.646dup|Cystinosis" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002093231" DateUpdated="2022-02-13" DateCreated="2022-02-13" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-07-02">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.3:c.646dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Cystinosis</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5463082" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_004937.3:c.646dup|OMIM:219750;219800;219900" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002811142" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.3:c.646dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219750" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219900" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7867321" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_004937.3:c.646dup|OMIM:219800" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004215220" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.3:c.646dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219800" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1604614" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5463082" TraitType="Disease" MappingType="XRef" MappingValue="219800" MappingRef="OMIM">
        <MedGen CUI="C2931187" Name="Nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1604614" TraitType="Disease" MappingType="XRef" MappingValue="C0268626" MappingRef="MedGen">
        <MedGen CUI="C0268626" Name="Juvenile nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5463082" TraitType="Disease" MappingType="XRef" MappingValue="219750" MappingRef="OMIM">
        <MedGen CUI="C2931013" Name="Ocular cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1604614" TraitType="Disease" MappingType="XRef" MappingValue="C1857413" MappingRef="MedGen">
        <MedGen CUI="C2931013" Name="Ocular cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4081291" TraitType="Disease" MappingType="Name" MappingValue="Cystinosis" MappingRef="Preferred">
        <MedGen CUI="C4316899" Name="Cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7867321" TraitType="Disease" MappingType="XRef" MappingValue="219800" MappingRef="OMIM">
        <MedGen CUI="C2931187" Name="Nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="950308" TraitType="Disease" MappingType="XRef" MappingValue="219800" MappingRef="OMIM">
        <MedGen CUI="C2931187" Name="Nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5463082" TraitType="Disease" MappingType="XRef" MappingValue="219900" MappingRef="OMIM">
        <MedGen CUI="C0268626" Name="Juvenile nephropathic cystinosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

